FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/03/083598 [Registered on: 27/03/2025] Trial Registered Prospectively
Last Modified On: 26/03/2025
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Other 
Public Title of Study   Study observing medicine being prescribed to patients with Psoriasis at SMS hospital, Jaipur 
Scientific Title of Study   An Observational study on Drug Prescription Pattern in Psoriasis Patients Attending Dermatology and Venereology Department at SMS Hospital, Jaipur, Rajasthan 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dinesh kumar 
Designation  Postgraduate Resident  
Affiliation  Sawai Man Singh Medical College Jaipur, Rajasthan, India, 302004 
Address  Department of Pharmacology, SMS Medical College, Jaipur, Rajasthan, India, 302004

Jaipur
RAJASTHAN
302004
India 
Phone  9887759136  
Fax    
Email  dineshsharma.ds09@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Chandan Verma 
Designation  Professor  
Affiliation  Sawai Man Singh Medical College Jaipur, Rajasthan, India, 302004 
Address  Department of Pharmacology, SMS Medical College, Jaipur, Rajasthan, India, 302004

Jaipur
RAJASTHAN
302004
India 
Phone  9414059213  
Fax    
Email  chandanverma1970@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Chandan Verma 
Designation  Professor  
Affiliation  Sawai Man Singh Medical College Jaipur, Rajasthan, India, 302004 
Address  Department of Pharmacology, SMS Medical College, Jaipur, Rajasthan, India, 302004


RAJASTHAN
302004
India 
Phone  9414059213  
Fax    
Email  chandanverma1970@gmail.com  
 
Source of Monetary or Material Support  
SMS Medical College and attached Hospital Jaipur, Rajasthan, India, 302004 
 
Primary Sponsor  
Name  Dr. Dinesh Kumar  
Address  Department of Pharmacology, SMS Medical College, Jaipur, Rajasthan, India, 302004 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
Nil  Nil 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Dinesh Kumar  Sawai Man Singh Hospital   Room no. 20, Dermatology and Venereology Department at SMS Hospital, Jaipur, Rajasthan , India,302004
Jaipur
RAJASTHAN 
9887759136

dineshsharma.ds09@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
ETHICS COMMITTEE, SMS MEDICAL COLLEGE AND ATTACHED HOSPITAL, JAIPUR  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: L40||Psoriasis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  1. Patients attending OPD of dermatology diagnosed with psoriasis.
2.Patients diagnosed with psoriasis with comorbidities.
3.Old and newly diagnosed patients
4.Patients who agreed to sign the informed consent form. 
 
ExclusionCriteria 
Details  1. Pregnant and lactating patients.
2. Inpatient department patients. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
1. Proportion of cases where drugs were prescribed according to STGs.
2.Average number of drugs per encounter.
3.Percentage of drugs prescribed with the generic name.
4.Percentage of encounters with antibiotics prescribed.
5.Percentage of encounters with injections prescribed.
6.Percentage of drugs prescribed from Essential Drugs List (EDL). 
At baseline 
 
Secondary Outcome  
Outcome  TimePoints 
1. To assess the health-related quality of life of diagnosed cases via DLQI scale.
2.To estimate the sociodemographic & clinical profile among recruited patients.
3.Patient will be sensitised for preventive measures for psoriasis. 
At baseline 
 
Target Sample Size   Total Sample Size="100"
Sample Size from India="100" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   10/04/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
Psoriasis is a chronic, inflammatory skin condition marked by red, scaly plaques, typically on the scalp, elbows, and knees, though it can affect other areas like the hands, feet, and trunk. It involves a combination of genetic predisposition and environmental triggers such as trauma, stress, or medications, and can lead to systemic issues in various organs. The disease is characterized by epidermal hyperproliferation, inflammatory infiltration, and abnormal angiogenesis. Symptoms commonly include itching, irritation, and pain, and psoriasis significantly impacts quality of life. Various forms of psoriasis exist, including plaque, guttate, pustular, and erythrodermic types.

Treatment varies based on disease severity, with mild psoriasis managed by topical treatments like corticosteroids, emollients, and vitamin D3 analogues. More severe cases require systemic therapies or phototherapy. Evaluating prescribing patterns is essential for ensuring rational drug use, as inappropriate prescribing can lead to ineffective treatment, increased costs, and adverse effects. Adherence to prescribed medication is crucial for successful treatment, and patient preferences, treatment efficacy, and comorbidities influence medication choices. Monitoring and optimizing drug use can help minimize side effects and improve treatment outcomes.
 
Close